Company intelligence / Profile preview

Longevity Health

Philadelphia, Pennsylvania, United States

Ownership: Private
Development stage: Other

Overview

Longevity Biotech focuses on developing novel synthetic peptide-based therapies that aim to “reset” immune dysfunction in neurodegenerative diseases, especially Parkinson’s Disease. They are currently expanding into other related indications and have received high-profile grants and partnerships, but no publicly available clinical trial results yet.

Therapeutic areas: Neurology
Modalities: PeptidesSmall molecule
Industry: Biotech

Partnerships

Michael J. Fox FoundationNational Multiple Sclerosis Society (US and Canada)National Institutes of HealthNational Science FoundationAdditional unspecified global partners

Beyond the preview

Go deeper on Longevity Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Longevity Health.

Explore the full profile